Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

American Oriental to Begin US Clinical Trial of TCM Drug

publication date: Mar 9, 2009

American Oriental Bioengineering (广西博科药业) will begin a US-based Phase I clinical trial of its oral TCM treatment for urinary incontinence, designed to gain approval of the drug from the FDA. AOB has marketed the UI drug in China since 2002 under the name Cease Enuresis Oral Capsule. The IND was based on pre-clinical work done in China to FDA standards. The clinical trials will be conducted in the US and China, though its goal is to show that AOBO-001, as the trial version is known, is effective for UI in American populations. More details...

Stock Symbol: (NYSE: AOB)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here